10-Q · May 8, 2026
Maravai LifeSciences reported strong results for Q1 2026 with a revenue of $65.8 million, exceeding expectations of $53.3 million, and showing a significant increase from $46.9 million in Q1 2025. The company achieved a…
Earnings analysis · 10-Q
MRVI earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
Maravai reported Q2 2026 revenue of $51.442 million and diluted EPS of $(0.02), with revenue lower than the unusually strong $66 million Q1 but higher than approximately $47 million in the prior-year quarter. Liquidity…
Read full summary
Maravai reported Q2 2026 revenue of $51.442 million and diluted EPS of $(0.02), with revenue lower than the unusually strong $66 million Q1 but higher than approximately $47 million in the prior-year quarter. Liquidity was $70.1 million against $150.0 million of Term Loan debt, while variable-rate exposure creates sensitivity to higher interest rates. The filing states that there were no material changes to the risk factors from the 2025 10-K and does not provide new quantitative guidance.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.02
What stood out
-
Revenue Improved Year Over Year
Q2 2026 revenue was $51.442 million, down from $66 million in Q1 2026 but up from approximately $47 million in Q2 2025. Reported diluted EPS was $(0.02), unchanged sequentially and improved from $(0.27) year over year.
-
Cash Balance Remains Material
Cash and cash equivalents totaled $70.1 million as of June 30, 2026, providing liquidity against the company’s debt obligations.
-
Revolver Remained Undrawn
The company had $150.0 million of outstanding Term Loan borrowings and no borrowings under its Revolving Credit Facility at June 30, 2026.
-
Controls Were Effective
Management stated that disclosure controls were effective at a reasonable assurance level as of June 30, 2026, and that there were no material changes in internal control over financial reporting during the quarter.
-
International Mix Remains Significant
International sales represented 40.0% of revenue in Q2 2026 and 43.7% for the first six months, although substantially all such sales were denominated in U.S. dollars.
What to watch
-
Variable-Rate Debt and Interest Expense
Borrowings under the 2026 Credit Agreement carry variable rates based on Term SOFR plus 5.00% or an alternate base rate plus 4.00%. A hypothetical 100-basis-point rate increase would have raised interest expense by approximately $0.5 million for the quarter and $1.2 million for the six-month period.
-
Debt Exceeds Cash
The company had $150.0 million of Term Loan borrowings compared with $70.1 million of cash and cash equivalents as of June 30, 2026. This creates meaningful balance-sheet leverage and limits financial flexibility if operating cash generation weakens.
-
Growing Foreign-Currency Exposure
International sales were 40.0% of quarterly revenue and 43.7% of six-month revenue. Although sales are substantially denominated in U.S. dollars, management said expanding international operations could increase exposure to foreign-exchange fluctuations, and the company has no foreign-currency hedging arrangements.
Management's outlook
The supplied 10-Q text does not provide quantitative revenue or EPS guidance, nor does it state whether the prior full-year revenue outlook of $205 million-$215 million was maintained, raised, lowered, or withdrawn.
Earlier filings 4
10-K · February 26, 2026
Maravai (MRVI) operates two reportable segments — TriLink (64% of 2025 revenue) and Cygnus (36% of 2025 revenue) — centered on nucleic acid products and biologics safety testing. The company shows a meaningful IP…
10-Q · November 7, 2025
Maravai LifeSciences reported a significant decline in Q3 2025 revenue, which dropped to $41.63 million from $69.03 million year-over-year, reflecting a 39.6% decrease. Net loss attributed to shareholders was $25.56…
10-Q · May 12, 2025
Maravai reported Q1 revenue of $46.85M and a net loss of $52.853M (net loss per Class A share $(0.21)). Revenue declined year-over-year from $64.179M to $46.85M, while loss from operations widened to $49.162M, driven in…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.